Low Serum Levels of Myeloid Progenitor Inhibitory Factor-1 Predict Good Response to Methotrexate in Rheumatoid Arthritis

Background. Although the benchmark in the treatment of rheumatoid arthritis remains methotrexate, only 70% of patients respond. Thus, there is a need for predictive biomarkers. This study planned to evaluate serum levels of myeloid progenitor inhibitory factor-1 (MPIF-1) and monocyte chemoattractant...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhir, Varun, Sandhu, Amit, Gupta, Nidhi, Dhawan, Veena, Sharma, Shefali, Sharma, Aman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886573/
https://www.ncbi.nlm.nih.gov/pubmed/24455421
http://dx.doi.org/10.1155/2013/460469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886573/
https://www.ncbi.nlm.nih.gov/pubmed/24455421
http://dx.doi.org/10.1155/2013/460469

Ejemplares similares